Hematology (all articles)
Minimum platelet count threshold before invasive procedures in cirrhosis: evolution of the guidelines
13 Mar, 2023 | 14:36h | UTC
Single-arm study | Gene therapy with Etranacogene Dezaparvovec for Hemophilia B
9 Mar, 2023 | 14:07h | UTCGene Therapy with Etranacogene Dezaparvovec for Hemophilia B – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Gene Therapy Beneficial for Patients With Hemophilia B – HealthDay
Cohort Study | Personalized progression prediction in patients with MGUS or smouldering multiple myeloma
9 Mar, 2023 | 13:59h | UTCInvited Commentary: The PANGEA model: catching the drift from precursor conditions to myeloma in individual patients – The Lancet Haematology
Commentary from the author on Twitter (thread – click for more)
‼️ The PANGEA Model is out now @TheLancetHaem ‼️
A 🧵on how PANGEA improves prediction accuracy of MGUS & SMM progression to #MultipleMyeloma & is the 1st model that is #personalized to the individual #mmsm patient! @LabGhobrial @DanaFarber | 1/https://t.co/e2rEWXLahT
— Annie (@anniencowan) February 28, 2023
Guideline | Management of severe peri-operative bleeding
8 Mar, 2023 | 14:18h | UTC
M-A | Oral iron supplementation and anemia in children according to schedule, duration, dose and cosupplementation
7 Mar, 2023 | 12:53h | UTCSummary:
The article is a systematic review and meta-analysis of 129 randomized trials on iron supplementation and anemia in children. The study aimed to identify the optimal schedule, duration, dose, and cosupplementation regimen for iron supplementation in children and adolescents aged under 20 years.
The results showed that frequent (3-7 times/week) and intermittent (1-2 times/week) iron supplementation could be equally effective at increasing hemoglobin and decreasing anemia, iron deficiency, and iron deficiency anemia.
The study supports WHO recommendations regarding the frequency, duration, and dose of iron supplementation, including 3 months annually of daily oral iron supplementation for children aged 6 months to 12 years living in regions with a high burden of anemia. However, it also suggests that weekly iron supplementation might be considered an alternative to the recommended daily regimen in some contexts, given evidence of similar efficacy.
Consensus Statement on the definition and classification of metabolic hyperferritinemia
3 Mar, 2023 | 13:58h | UTCConsensus Statement on the definition and classification of metabolic hyperferritinaemia – Nature Reviews Endocrinology (if the link is paywalled, try this one)
Review | Practical guide for anticoagulant and antiplatelet reversal in clinical practice
3 Mar, 2023 | 13:42h | UTCPractical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice – Pharmacy
The European guideline on management of major bleeding and coagulopathy following trauma
2 Mar, 2023 | 13:04h | UTC
Review | Platelet aggregation inhibitors and anticoagulants in gastroenterological and visceral surgical procedures
1 Mar, 2023 | 14:03h | UTC
RCT | Momelotinib vs. danazol in symptomatic patients with anemia and myelofibrosis
1 Mar, 2023 | 13:39h | UTCMomelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study – The Lancet (link to abstract – $ for full-text)
Review | Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
28 Feb, 2023 | 14:00h | UTCAntiphospholipid syndrome: advances in diagnosis, pathogenesis, and management – The BMJ
Cohort Study | Risk of second primary malignancies in patients with chronic lymphocytic leukemia
28 Feb, 2023 | 13:27h | UTC
Commentary on Twitter
Our recent population-based study shows that patients with chronic lymphocytic leukemia (CLL) have an increased risk of developing second primary malignancies (SPMs) in the long term. 1/3#CLLsm #OpenAccess #NKRdata #IKNL @BloodCancerJnl @IKNL https://t.co/epgVnnwv2W
— Dr. Avinash Dinmohamed (@ADinmohamed) January 19, 2023
Single-arm study | Two-year outcomes of Valoctocogene Roxaparvovec therapy for Hemophilia A
27 Feb, 2023 | 12:51h | UTCTwo-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In the GENEr8-1 trial, participants with hemophilia A received B-domain–deleted factor VIII gene therapy delivered in an AAV5 vector. A decrease in annualized bleeding rates was maintained for 2 years despite declining factor VIII levels. https://t.co/hYy3pT8ssa#hematology pic.twitter.com/HuJQa0HiTR
— NEJM (@NEJM) February 23, 2023
Sepsis-induced coagulopathy: an update on pathophysiology, biomarkers, and current guidelines
27 Feb, 2023 | 12:36h | UTCSepsis-Induced Coagulopathy: An Update on Pathophysiology, Biomarkers, and Current Guidelines – Life
Related:
Review | How to manage coagulopathies in critically ill patients
M-A | COVID-19 convalescent plasma outpatient therapy may prevent hospitalizations
23 Feb, 2023 | 13:37h | UTC
Single-arm study | Andexanet Alfa seems effective for the reduction of bleeding associated with factor Xa inhibitors
22 Feb, 2023 | 12:29h | UTCFinal Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors – Circulation
Review | How to manage coagulopathies in critically ill patients
21 Feb, 2023 | 11:43h | UTCHow to manage coagulopathies in critically ill patients – Intensive Care Medicine
Commentary on Twitter
Coagulopathies severe/frequent complication in #ICU: how to manage??
🩸 hemorrhagic coagulopathies: non‑malignant & malignant
🩸 thrombotic c.: sepsis‑induced & solid cancer‑associated
🩸 managing hemorrhagic c.
🩸(preventing &) managing thrombotic c.
🖇️ https://t.co/CKqzT7dcoH pic.twitter.com/SvpPNf0oGO— Intensive Care Medicine (@yourICM) February 18, 2023
RCT | Testing equivalence of two doses of intravenous iron to treat iron deficiency in pregnancy
14 Feb, 2023 | 10:31h | UTC
RCT | Ide-cel (a CAR-T cell treatment) vs. standard regimens in relapsed and refractory multiple myeloma
13 Feb, 2023 | 12:41h | UTCIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma – HealthDay
Ide-cel Improves PFS vs SOC in Relapsed/Refractory Multiple Myeloma – OncLive
RCT | Allo-HCT vs. standard consolidation chemotherapy in patients with intermediate-risk AML
13 Feb, 2023 | 12:40h | UTCAllogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
Rand trial suggests pts with intermediate-risk AML & matched donor have a significantly improved disease free-survival with allo-HCT during first complete remission (69% vs. 40%) but similar overall surv w/consol chemo & allo HCT only after relapse. https://t.co/TJR9fqcYc9
— JAMA Oncology (@JAMAOnc) February 9, 2023
Review | Management of adult patients with hematological malignancies in critical care
10 Feb, 2023 | 13:45h | UTCManagement of adult patients with haematological malignancies in critical care – Anaesthesia
M-A | Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia
9 Feb, 2023 | 13:30h | UTC
Cohort Study | Risk of primary hematologic cancers following incident non-metastatic breast cancer
8 Feb, 2023 | 12:11h | UTC
M-A | Heparin full-dose anticoagulation is beneficial for non-critically ill COVID-19 patients
7 Feb, 2023 | 14:06h | UTCRelated:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Podcast | Hemochromatosis pearls
7 Feb, 2023 | 13:53h | UTC#380 Hemochromatosis with Elliot Tapper – The Curbsiders